Literature DB >> 9014294

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.

D F Nixon1, C Hioe, P D Chen, Z Bian, P Kuebler, M L Li, H Qiu, X M Li, M Singh, J Richardson, P McGee, T Zamb, W Koff, C Y Wang, D O'Hagan.   

Abstract

Peptides from Plasmodium berghei circumsporozoite protein (CS) and influenza A virus nucleoprotein (NP) were entrapped in microparticles prepared from poly (lactide-co-glycolide) polymers, and the microparticles were administered parenterally to mice. After immunization with single or multiple doses, splenocytes were tested for a cytotoxic T cell (CTL) response and high levels of CTL activity were detected. The CTL induced were CD8+, MHC class I restricted, and could recognize virus infected cells. Peptide entrapped in microparticles of mean size < 500 nm were better inducers of CTL than larger microparticles (mean > 2 microns and above). Microparticles could also be used to deliver lipid modified peptides (lipopeptides) and elicited higher levels of cytolytic activity than either free peptide in microparticles or lipopeptide alone. Microparticles provide a novel way of inducing a CTL response using synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014294     DOI: 10.1016/s0264-410x(96)00099-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro.

Authors:  M E Christine Lutsiak; Deborah R Robinson; Conrad Coester; Glen S Kwon; John Samuel
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 3.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

4.  Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo.

Authors:  Yu-Zhang Wu; Jian-Ping Zhao; Ying Wan; Zheng-Cai Jia; Wei Zhou; Jiang Bian; Bing Ni; Li-Yun Zou; Yan Tang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 5.  Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.

Authors:  José M Morachis; Enas A Mahmoud; Adah Almutairi
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

6.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

8.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

9.  Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents.

Authors:  R Audran; Y Men; P Johansen; B Gander; G Corradin
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

10.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.